Literature DB >> 10680094

The Toronto Cardiac Rehabilitation and Secondary Prevention Program: 1968 into the new millennium.

L F Hamm1, T Kavanagh.   

Abstract

Given our approach to the cardiac rehabilitation process, which is reflected in the program structure and services and our high patient volume, this program model is effective for us. The model permits us to treat relatively large number of patients with relatively small numbers of staff. On average, a patient attends 32 supervised exercise sessions at the Centre over the course of 12 months. This is actually fewer supervised sessions than the popular model of 3 times per week for 12 weeks. However, the 12-month program provides an additional 9 months to work with patients on heart-healthy lifestyle modifications. At the same time, we realize our model is not the model of choice for all people in all settings for a variety of reasons. We trust that some elements of our program may be of interest and beneficial to some readers. Undoubtedly, the program will continue to evolve and develop into the future. Currently, we are conducting a cardiac rehabilitation outcomes study in an effort to determine the appropriate duration of cardiac rehabilitation to achieve optimal physiological, psychological, and cost benefits for patients. This study involves more than 700 patients and the results are intended to help us further refine the program structure and selected program elements. As the new millennium approaches, healthcare system reforms and continuing changes in the delivery of medical care to cardiac patients present opportunities, challenges, and some uncertainties for cardiac rehabilitation. To continue our services to patients and the medical community, cardiac rehabilitation programs will need to identify and develop even more innovative and effective concepts in response to ever-changing local, regional, and national issues.

Entities:  

Mesh:

Year:  2000        PMID: 10680094     DOI: 10.1097/00008483-200001000-00003

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil        ISSN: 0883-9212            Impact factor:   2.081


  7 in total

1.  Brain derived neurotrophic factor, cardiopulmonary fitness and cognition in patients with coronary artery disease.

Authors:  W Swardfager; N Herrmann; S Marzolini; M Saleem; P Shammi; P I Oh; P R Albert; M Daigle; A Kiss; K L Lanctôt
Journal:  Brain Behav Immun       Date:  2011-04-30       Impact factor: 7.217

2.  Feasibility and effects of adapted cardiac rehabilitation after stroke: a prospective trial.

Authors:  Ada Tang; Susan Marzolini; Paul Oh; William E McIlroy; Dina Brooks
Journal:  BMC Neurol       Date:  2010-06-09       Impact factor: 2.474

3.  Exercise Training Increases Parietal Lobe Cerebral Blood Flow in Chronic Stroke: An Observational Study.

Authors:  Andrew D Robertson; Susan Marzolini; Laura E Middleton; Vincenzo S Basile; Paul I Oh; Bradley J MacIntosh
Journal:  Front Aging Neurosci       Date:  2017-09-29       Impact factor: 5.750

4.  Impact of 12-week exercise program on biomarkers of gut barrier integrity in patients with coronary artery disease.

Authors:  Vivian Feng; Kritleen K Bawa; Susan Marzolini; Alex Kiss; Paul Oh; Nathan Herrmann; Krista L Lanctôt; Damien Gallagher
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

5.  The Relationship between Oxidative Stress and Subjective Sleep Quality in People with Coronary Artery Disease.

Authors:  Vivian Feng; Shankar Tumati; Ruoding Wang; Kritleen K Bawa; Damien Gallagher; Nathan Herrmann; Susan Marzolini; Paul Oh; Ana Andreazza; Krista L Lanctôt
Journal:  Brain Sci       Date:  2022-08-12

6.  Cardiopulmonary fitness correlates with regional cerebral grey matter perfusion and density in men with coronary artery disease.

Authors:  Bradley J MacIntosh; Walter Swardfager; David E Crane; Nipuni Ranepura; Mahwesh Saleem; Paul I Oh; Bojana Stefanovic; Nathan Herrmann; Krista L Lanctôt
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

7.  Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Graham Mazereeuw; Nathan Herrmann; Paul I Oh; David W L Ma; Cheng Tao Wang; Alexander Kiss; Krista L Lanctôt
Journal:  J Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.